Rheumatology Unit, University of Verona.
Internal Medicine Unit, University of Verona.
Reumatismo. 2021 Jan 18;72(4):189-196. doi: 10.4081/reumatismo.2020.1333.
The role of 25-OH-vitamin D in the assessment of coronavirus disease 19 (COVID-19) has not been investigated. We sought to investigate the prevalence of 25-OH-vitamin D deficiency among COVID-19 patients, and to determine the associations between 25-OH-vitamin D status and the severity of the disease. We have conducted a retrospective observational study of COVID-19 patients admitted to the University of Verona Hospital Trust. Demographic, clinical and biochemical parameters were collected at hospital admission, and serum 25-OH-vitamin D levels were measured. The following outcomes were assessed: arterial partial oxygen pressure (PaO2); C-reactive protein (CRP); length of hospitalization; requirement of oxygen therapy; non-invasive ventilation (NIV); mechanical ventilation; and death. Among 61 patients enrolled, 72.1% was 25-OH-vitamin D deficient (<20 ng/mL) and 57.4% had 25-OHvitamin D <15 ng/mL. Patients with arterial PaO2 <60 mmHg had significantly lower mean 25-OH-vitamin D levels compared to patients with PaO2 ≥60 mmHg (13.3 ng/mL vs 20.4 ng/mL respectively, p=0.03). Vitamin D deficiency was associated with 3-fold higher risk of having arterial pO2 <60 mmHg. 25-OH-vitamin D deficiency was associated with increased CRP and dyspnea. 25-OH-vitamin D deficiency was associated with more severe systemic inflammatory response and respiratory failure in COVID-19 patients.
25-羟维生素 D 在评估新型冠状病毒病 19(COVID-19)中的作用尚未得到研究。我们旨在调查 COVID-19 患者中 25-羟维生素 D 缺乏症的患病率,并确定 25-羟维生素 D 状态与疾病严重程度之间的关系。我们对入住维罗纳大学医院信托基金会的 COVID-19 患者进行了回顾性观察性研究。在入院时收集了人口统计学、临床和生化参数,并测量了血清 25-羟维生素 D 水平。评估了以下结果:动脉血氧分压(PaO2);C 反应蛋白(CRP);住院时间;氧疗需求;无创通气(NIV);机械通气;和死亡。在纳入的 61 名患者中,72.1%的患者 25-羟维生素 D 缺乏(<20ng/mL),57.4%的患者 25-羟维生素 D<15ng/mL。动脉 PaO2<60mmHg 的患者的平均 25-羟维生素 D 水平明显低于 PaO2≥60mmHg 的患者(分别为 13.3ng/mL 和 20.4ng/mL,p=0.03)。维生素 D 缺乏与动脉 pO2<60mmHg 的风险增加 3 倍相关。25-羟维生素 D 缺乏与 CRP 和呼吸困难增加有关。25-羟维生素 D 缺乏与 COVID-19 患者更严重的全身炎症反应和呼吸衰竭相关。